Cancer reports最新文献

A New Radiotranscriptomic Approach to Analyze Combined Sets of T3b Stage-Specific Genes and Radiomic Features in Prostate Cancer 一种新的放射转录组学方法分析前列腺癌T3b分期特异性基因组合和放射组学特征。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-12 DOI: 10.1002/cnr2.70391

Qian Yang, Peng Tang, Jiao Mo, Qiuyang Li, Jiahui Huang, Xiaoyu Han, Hao Xu, Xi Liu, Jie Tang

Background

Current clinical staging of prostate cancer (PCa) using the tumor-node-metastasis (TNM) system and serum biomarkers remains limited in distinguishing locally advanced (T3b) PCa from organ-confined (T2c) disease.

Aims

Building on our previous biomarker discovery in differentiating PCa from that of benign prostatic hyperplasia, this study pioneers a radiotranscriptomic model to distinguish T3b stage PCa from T2c stage PCa by integrating contrast-enhanced ultrasound (CEUS) radiomics with stage-specific transcriptomic signatures, addressing a critical knowledge gap in precision staging.

Methods and Results

This prospective study was approved by the review board of Chinese PLA General Hospital (S2021-565-01), and all participants provided written informed consent. Transrectal B-mode ultrasound images and contrast-enhanced ultrasound images on two imaging planes were prospectively analyzed in 48 patients with biopsy-confirmed PCa (35 patients with stage T2c and 13 with stage T3b). Textural features were evaluated using microvascular ultrasonography and contrast-enhanced ultrasound. Radiomic data were then retrieved from all modes. An across-the-board investigation of mRNA and miRNA expressions was also performed in the two PCa stages. Six biomarkers (frizzled 4, ribosomal protein S7, ribosomal protein L29, miR-374c, miR-9, and miR-6510) were identified to differentiate T3b stage from T2c stage. The area under the curve (AUC) values of the combined set (AUC = 0.887, 0.956, and 0.996 for random forest, naïve Bayes, and support vector machine, respectively) and radiomic features alone (AUC = 0.921, 0.957, and 0.998, respectively) were found to be more accurate than those of the transcriptomic data alone (AUC = 0.583, 0.716, and 0.898, respectively) or clinical features alone (AUC = 0.585, 0.675, and 0.953, respectively). The PCa gene regulatory network comprised of four miRNAs (miR-148, miR-141, miR-342, and miR-210) may contribute to accelerating tumor progression.

Conclusion

We established the new radiotranscriptomic signatures specifically optimized for differentiating T3b stage from T2c stage by decoding stage-specific imaging-genomic crosstalk. This new approach may overcome TNM staging limitations.

背景：目前使用肿瘤-淋巴结-转移（TNM）系统和血清生物标志物对前列腺癌（PCa）的临床分期在区分局部晚期（T3b）前列腺癌和器官局限性（T2c）前列腺癌方面仍然有限。目的：在我们之前发现的鉴别前列腺癌与良性前列腺增生的生物标志物的基础上，本研究建立了一种放射转录组学模型，通过将对比增强超声（CEUS）放射组学与分期特异性转录组学特征相结合，来区分T3b期和T2c期的前列腺癌，解决了精确分期的关键知识空白。方法和结果：本前瞻性研究经中国人民解放军总医院审查委员会批准（S2021-565-01），所有参与者均提供书面知情同意。回顾性分析48例经直肠活检证实的前列腺癌患者（T2c期35例，T3b期13例）的经直肠b超及两个成像平面的超声增强图像。采用微血管超声和增强超声对纹理特征进行评价。然后从所有模式中检索放射学数据。在两个PCa阶段也进行了mRNA和miRNA表达的全面调查。鉴定出6种生物标志物（卷曲4、核糖体蛋白S7、核糖体蛋白L29、miR-374c、miR-9和miR-6510）用于区分T3b期和T2c期。联合集（随机森林、naïve贝叶斯和支持向量机的AUC分别为0.887、0.956和0.996）和放射组学特征（AUC分别为0.921、0.957和0.998）的曲线下面积（AUC）值比单独使用转录组学数据（AUC分别为0.583、0.716和0.898）或单独使用临床特征（AUC分别为0.585、0.675和0.953）的曲线下面积（AUC）值更准确。由四种mirna （miR-148、miR-141、miR-342和miR-210）组成的PCa基因调控网络可能有助于加速肿瘤进展。结论：通过解码阶段特异性成像-基因组串扰，我们建立了专门用于区分T3b期和T2c期的新的放射转录组学特征。这种新方法可能克服TNM分期的限制。

{"title":"A New Radiotranscriptomic Approach to Analyze Combined Sets of T3b Stage-Specific Genes and Radiomic Features in Prostate Cancer","authors":"Qian Yang, Peng Tang, Jiao Mo, Qiuyang Li, Jiahui Huang, Xiaoyu Han, Hao Xu, Xi Liu, Jie Tang","doi":"10.1002/cnr2.70391","DOIUrl":"10.1002/cnr2.70391","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Current clinical staging of prostate cancer (PCa) using the tumor-node-metastasis (TNM) system and serum biomarkers remains limited in distinguishing locally advanced (T3b) PCa from organ-confined (T2c) disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Building on our previous biomarker discovery in differentiating PCa from that of benign prostatic hyperplasia, this study pioneers a radiotranscriptomic model to distinguish T3b stage PCa from T2c stage PCa by integrating contrast-enhanced ultrasound (CEUS) radiomics with stage-specific transcriptomic signatures, addressing a critical knowledge gap in precision staging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This prospective study was approved by the review board of Chinese PLA General Hospital (S2021-565-01), and all participants provided written informed consent. Transrectal B-mode ultrasound images and contrast-enhanced ultrasound images on two imaging planes were prospectively analyzed in 48 patients with biopsy-confirmed PCa (35 patients with stage T2c and 13 with stage T3b). Textural features were evaluated using microvascular ultrasonography and contrast-enhanced ultrasound. Radiomic data were then retrieved from all modes. An across-the-board investigation of mRNA and miRNA expressions was also performed in the two PCa stages. Six biomarkers (frizzled 4, ribosomal protein S7, ribosomal protein L29, miR-374c, miR-9, and miR-6510) were identified to differentiate T3b stage from T2c stage. The area under the curve (AUC) values of the combined set (AUC = 0.887, 0.956, and 0.996 for random forest, naïve Bayes, and support vector machine, respectively) and radiomic features alone (AUC = 0.921, 0.957, and 0.998, respectively) were found to be more accurate than those of the transcriptomic data alone (AUC = 0.583, 0.716, and 0.898, respectively) or clinical features alone (AUC = 0.585, 0.675, and 0.953, respectively). The PCa gene regulatory network comprised of four miRNAs (miR-148, miR-141, miR-342, and miR-210) may contribute to accelerating tumor progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We established the new radiotranscriptomic signatures specifically optimized for differentiating T3b stage from T2c stage by decoding stage-specific imaging-genomic crosstalk. This new approach may overcome TNM staging limitations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70391","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Efficacy of Radiofrequency Ablation in Treating Nonmetastatic Medullary Thyroid Carcinoma: A Case Study 射频消融治疗非转移性甲状腺髓样癌的疗效：一例研究。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-10 DOI: 10.1002/cnr2.70419

Hojat Ebrahiminik, Hossein Chegeni, Haleh Chehrehgosha

Background

Radiofrequency ablation (RFA) can be an alternative management method for patients who are not candidates for surgery or who refuse it. There are limited data concerning the role of RFA in patients with medullary thyroid carcinoma (MTC). This case is presented to discuss the efficacy of RFA in the management of nonmetastatic MTC.

Case

In this report, we present the case of an 83-year-old male with MTC who refused thyroidectomy. RFA was performed and he was followed for 1 year. In this case, RFA resulted in significant reductions in tumor size and calcitonin levels without any significant complications.

Conclusion

This research indicates that Radiofrequency Ablation (RFA) can yield acceptable results in the management of Medullary Thyroid Cancer (MTC). However, ongoing investigation remains crucial to clarify long-term outcomes and to compare RFA's efficacy against conventional management methods.

背景：射频消融（RFA）可以作为不适合手术或拒绝手术的患者的另一种治疗方法。关于RFA在甲状腺髓样癌（MTC）患者中的作用的数据有限。本病例是为了讨论RFA在非转移性MTC治疗中的疗效。病例：在本报告中，我们报告一例83岁男性MTC患者拒绝甲状腺切除术。术后随访1年。在这个病例中，RFA导致肿瘤大小和降钙素水平的显著减少，没有任何明显的并发症。结论：射频消融（RFA）治疗甲状腺髓样癌（MTC）疗效满意。然而，正在进行的研究对于澄清长期结果和比较RFA与传统管理方法的疗效仍然至关重要。

{"title":"The Efficacy of Radiofrequency Ablation in Treating Nonmetastatic Medullary Thyroid Carcinoma: A Case Study","authors":"Hojat Ebrahiminik, Hossein Chegeni, Haleh Chehrehgosha","doi":"10.1002/cnr2.70419","DOIUrl":"10.1002/cnr2.70419","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Radiofrequency ablation (RFA) can be an alternative management method for patients who are not candidates for surgery or who refuse it. There are limited data concerning the role of RFA in patients with medullary thyroid carcinoma (MTC). This case is presented to discuss the efficacy of RFA in the management of nonmetastatic MTC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>In this report, we present the case of an 83-year-old male with MTC who refused thyroidectomy. RFA was performed and he was followed for 1 year. In this case, RFA resulted in significant reductions in tumor size and calcitonin levels without any significant complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This research indicates that Radiofrequency Ablation (RFA) can yield acceptable results in the management of Medullary Thyroid Cancer (MTC). However, ongoing investigation remains crucial to clarify long-term outcomes and to compare RFA's efficacy against conventional management methods.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12690977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Myeloid Leukemia Secondary to Radiation Therapy for Rectal Cancer: A Case Report 直肠癌放射治疗继发急性髓系白血病1例报告。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-09 DOI: 10.1002/cnr2.70379

Ahmad Alkhaledi, Laila Alhaj Hussaen, Linda Kahla, Baraa Sammoud, Suha Giselle Ghanem

Background

Therapy-related AML (t-AML) is a subtype of acute myeloid leukemia (AML) that arises in the bone marrow and primarily affects white blood cells. It is associated with prior exposure to cytotoxic agents, including chemotherapy and radiotherapy. The risk of the disease increases with age and treatment intensity. Although t-AML represents 25%–30% of all AML cases, its occurrence following radiotherapy is relatively rare. Diagnosis is confirmed via bone marrow biopsy, with differential diagnoses including other leukemias, lymphomas, and myelodysplastic syndromes. Prognosis is generally poor. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective curative option, though elderly patients often have limited eligibility due to comorbidities and poor performance status.

Case

Five years after treatment for stage IIA rectal cancer, including radiotherapy, chemotherapy, and surgery, a 77-year-old male smoker presented with fatigue, weight loss, progressive dyspnea, headache, dizziness, blurred vision, and melena. Physical examination revealed pallor, purpura, skin crusts, and pustules. Laboratory findings showed anemia, thrombocytopenia, and circulating blasts. Bone marrow biopsy confirmed lymphoid infiltration. He was diagnosed with therapy-related AML (t-AML). Despite receiving three cycles of Azacitidine, he died of septic shock 7 months later.

Conclusion

This case highlights the rare development of therapy-related acute myeloid leukemia in a colorectal cancer survivor following combined pelvic radiation and capecitabine plus oxaliplatin (CAPOX) chemotherapy, underscoring the importance of long-term hematologic surveillance in such patients.

背景：治疗相关性AML （t-AML）是急性髓性白血病（AML）的一种亚型，发生于骨髓，主要影响白细胞。它与先前暴露于细胞毒性物质，包括化疗和放疗有关。患此病的风险随着年龄和治疗强度的增加而增加。虽然t-AML占所有AML病例的25%-30%，但其在放疗后的发生相对罕见。通过骨髓活检确诊，鉴别诊断包括其他白血病、淋巴瘤和骨髓增生异常综合征。预后一般较差。同种异体造血干细胞移植（Allogeneic hematopoietic stem cell transplantation, alloo - hsct）仍然是最有效的治疗选择，尽管老年患者通常由于合共病和表现不佳而资格有限。病例：一名77岁男性吸烟者在接受IIA期直肠癌放疗、化疗和手术治疗5年后，表现为疲劳、体重减轻、进行性呼吸困难、头痛、头晕、视力模糊和黑黑。体格检查显示苍白，紫癜，皮肤结痂和脓疱。实验室结果显示贫血、血小板减少和循环原细胞。骨髓活检证实淋巴浸润。他被诊断为治疗相关性AML （t-AML）。尽管接受了三个周期的阿扎胞苷治疗，但他在7个月后死于感染性休克。结论：该病例强调了在盆腔放射联合卡培他滨加奥沙利铂（CAPOX）化疗后，结直肠癌幸存者罕见的治疗相关急性髓系白血病的发展，强调了对此类患者进行长期血液学监测的重要性。

{"title":"Acute Myeloid Leukemia Secondary to Radiation Therapy for Rectal Cancer: A Case Report","authors":"Ahmad Alkhaledi, Laila Alhaj Hussaen, Linda Kahla, Baraa Sammoud, Suha Giselle Ghanem","doi":"10.1002/cnr2.70379","DOIUrl":"10.1002/cnr2.70379","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Therapy-related AML (t-AML) is a subtype of acute myeloid leukemia (AML) that arises in the bone marrow and primarily affects white blood cells. It is associated with prior exposure to cytotoxic agents, including chemotherapy and radiotherapy. The risk of the disease increases with age and treatment intensity. Although t-AML represents 25%–30% of all AML cases, its occurrence following radiotherapy is relatively rare. Diagnosis is confirmed via bone marrow biopsy, with differential diagnoses including other leukemias, lymphomas, and myelodysplastic syndromes. Prognosis is generally poor. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective curative option, though elderly patients often have limited eligibility due to comorbidities and poor performance status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Five years after treatment for stage IIA rectal cancer, including radiotherapy, chemotherapy, and surgery, a 77-year-old male smoker presented with fatigue, weight loss, progressive dyspnea, headache, dizziness, blurred vision, and melena. Physical examination revealed pallor, purpura, skin crusts, and pustules. Laboratory findings showed anemia, thrombocytopenia, and circulating blasts. Bone marrow biopsy confirmed lymphoid infiltration. He was diagnosed with therapy-related AML (t-AML). Despite receiving three cycles of Azacitidine, he died of septic shock 7 months later.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights the rare development of therapy-related acute myeloid leukemia in a colorectal cancer survivor following combined pelvic radiation and capecitabine plus oxaliplatin (CAPOX) chemotherapy, underscoring the importance of long-term hematologic surveillance in such patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to “Objective Assessment of Physical Activity in Breast Cancer Survivors: Associations With Adiposity and Metabolic Parameters of Glucose and Insulin—Insights From NHANES” 修正了“乳腺癌幸存者体育活动的客观评估：与肥胖和葡萄糖和胰岛素代谢参数的关联——来自NHANES的见解”。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-09 DOI: 10.1002/cnr2.70424

J. J. Cao-Alvira, E. F. Luciano, M. Sauane, and C. de la Parra, “Objective Assessment of Physical Activity in Breast Cancer Survivors: Associations With Adiposity and Metabolic Parameters of Glucose and Insulin—Insights From NHANES,” Cancer Reports 8, no. 9 (2025): e70339, https://doi.org/10.1002/cnr2.70339.

In the published article, affiliation 5 is incomplete. It currently reads:

5 City University of New York, New York, New York, USA

It should read:

5 Ph.D. Programs in Biochemistry and Biology, The Graduate Center, City University of New York, New York, New York, USA

We apologize for this error.

J. J. Cao-Alvira， E. F. Luciano， M. Sauane， C. de la Parra，“乳腺癌幸存者身体活动的客观评估：与肥胖和葡萄糖和胰岛素代谢参数的关联——来自NHANES的观察”，癌症杂志，第8期。9 (2025): e70339, https://doi.org/10.1002/cnr2.70339.In已发表文章，隶属关系5不完整。它现在是：5 City University of New York， New York, New York， usa它应该是：5 Ph.D. Programs in Biochemistry and Biology, The Graduate Center, City University of New York, New York, usa。我们为这个错误道歉。

引用次数: 0

Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib 奥西替尼联合阿法替尼治疗表皮生长因子受体L861R突变阳性肺腺癌2例。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-05 DOI: 10.1002/cnr2.70420

Kei Kagawa, Takeshi Masuda, Kiyofumi Shimoji, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori

Background

Epidermal growth factor receptor (EGFR) mutations are detected in approximately 40%–50% of patients with lung adenocarcinoma in Asian populations and in around 10% of patients in Western populations. Among these, the EGFR L861R mutation is uncommon and undetectable using conventional polymerase chain reaction methods. Recently, clinically available next-generation sequencing (NGS) has been used to detect L861R mutations, potentially increasing the number of identified cases of L861R-positive non-small cell lung cancer. Herein, we present two cases of EGFR L861R-mutated lung adenocarcinoma treated with afatinib and osimertinib to evaluate the clinical efficacy and tolerability of these targeted therapies.

Case

Case 1: A 63-year-old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received afatinib 40 mg/day. Computer tomography (CT) on Day 49 showed shrinkage of the primary tumor, accompanied by a decrease in tumor markers. The afatinib dose was reduced to 30 mg/day due to Grade 1 diarrhea and an acneiform rash. Ground-glass opacities were subsequently observed around the tumor. Although pneumonitis was initially suspected, the findings were subsequently considered consistent with carcinomatous lymphangitis. Consequently, afatinib was discontinued on Day 56. Case 2: An 83-year-old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received osimertinib 80 mg/day. Afatinib was avoided due to concerns regarding tolerability in the elderly. CT imaging on Day 14 showed tumor shrinkage with reduced attenuation and decreased levels of tumor markers. However, osimertinib was discontinued on Day 104 due to a Grade 3 skin rash. The response to osimertinib was evaluated as stable disease. Following treatment discontinuation, the disease progressed to multiple brain metastases, and supportive care was initiated.

Conclusion

Here, we present the first case showing the anti-tumor efficacy of afatinib and the second case showing the anti-tumor efficacy of osimertinib in a patient with EGFR L861R-positive lung adenocarcinoma. Despite their short treatment durations, afatinib and osimertinib may have potential clinical activity in patients with EGFR L861R-positive lung cancer.

背景：在亚洲人群中，大约40%-50%的肺腺癌患者检测到表皮生长因子受体（EGFR）突变，而在西方人群中，大约10%的患者检测到表皮生长因子受体突变。其中，EGFR L861R突变是不常见的，使用传统的聚合酶链反应方法无法检测到。最近，临床可用的下一代测序（NGS）已被用于检测L861R突变，可能会增加L861R阳性非小细胞肺癌的确诊病例数量。在此，我们报告了两例EGFR l861r突变的肺腺癌，用阿法替尼和奥西替尼治疗，以评估这些靶向治疗的临床疗效和耐受性。病例1:63岁男性肺腺癌携带EGFR L861R突变（c期IVB）接受阿法替尼40mg /天。第49天的计算机断层扫描（CT）显示原发肿瘤缩小，并伴有肿瘤标志物减少。由于1级腹泻和痤疮样皮疹，阿法替尼剂量减少到30mg /天。随后在肿瘤周围观察到毛玻璃混浊。虽然最初怀疑是肺炎，但结果随后被认为与癌性淋巴管炎一致。因此，阿法替尼在第56天停用。病例2：一名83岁男性肺腺癌患者携带EGFR L861R突变（c期IVB），接受奥希替尼80mg /天。由于考虑到老年人的耐受性，避免使用阿法替尼。第14天的CT成像显示肿瘤缩小，衰减减少，肿瘤标志物水平降低。然而，由于3级皮疹，奥希替尼在第104天停药。对奥西替尼的反应被评价为病情稳定。停止治疗后，病情发展为多发性脑转移，并开始了支持性治疗。结论：本文报道了1例EGFR l861r阳性肺腺癌患者中显示阿法替尼抗肿瘤疗效的第一例，奥西替尼显示抗肿瘤疗效的第二例。尽管治疗时间短，但阿法替尼和奥西替尼在EGFR l861r阳性肺癌患者中可能具有潜在的临床活性。

{"title":"Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib","authors":"Kei Kagawa, Takeshi Masuda, Kiyofumi Shimoji, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori","doi":"10.1002/cnr2.70420","DOIUrl":"10.1002/cnr2.70420","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epidermal growth factor receptor (EGFR) mutations are detected in approximately 40%–50% of patients with lung adenocarcinoma in Asian populations and in around 10% of patients in Western populations. Among these, the EGFR L861R mutation is uncommon and undetectable using conventional polymerase chain reaction methods. Recently, clinically available next-generation sequencing (NGS) has been used to detect L861R mutations, potentially increasing the number of identified cases of L861R-positive non-small cell lung cancer. Herein, we present two cases of EGFR L861R-mutated lung adenocarcinoma treated with afatinib and osimertinib to evaluate the clinical efficacy and tolerability of these targeted therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>Case 1: A 63-year-old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received afatinib 40 mg/day. Computer tomography (CT) on Day 49 showed shrinkage of the primary tumor, accompanied by a decrease in tumor markers. The afatinib dose was reduced to 30 mg/day due to Grade 1 diarrhea and an acneiform rash. Ground-glass opacities were subsequently observed around the tumor. Although pneumonitis was initially suspected, the findings were subsequently considered consistent with carcinomatous lymphangitis. Consequently, afatinib was discontinued on Day 56. Case 2: An 83-year-old man with lung adenocarcinoma harboring an EGFR L861R mutation (cStage IVB) received osimertinib 80 mg/day. Afatinib was avoided due to concerns regarding tolerability in the elderly. CT imaging on Day 14 showed tumor shrinkage with reduced attenuation and decreased levels of tumor markers. However, osimertinib was discontinued on Day 104 due to a Grade 3 skin rash. The response to osimertinib was evaluated as stable disease. Following treatment discontinuation, the disease progressed to multiple brain metastases, and supportive care was initiated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Here, we present the first case showing the anti-tumor efficacy of afatinib and the second case showing the anti-tumor efficacy of osimertinib in a patient with EGFR L861R-positive lung adenocarcinoma. Despite their short treatment durations, afatinib and osimertinib may have potential clinical activity in patients with EGFR L861R-positive lung cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic Ultrasound-Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment 内窥镜超声引导下的乳腺癌肝转移组织采集能够检测治疗所需的生物标志物。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-05 DOI: 10.1002/cnr2.70414

Yuichi Takano, Naoki Tamai, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Fumitaka Niiya, Naotaka Maruoka, Tatsuya Yamagami, Masatsugu Nagahama

Background

Evaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. Since biomarker expression may differ between primary and metastatic lesions, biopsy of metastatic sites is recommended whenever feasible. The liver is a common metastatic site for breast cancer, and percutaneous biopsy has traditionally been the standard approach. Recently, endoscopic ultrasound-guided tissue acquisition (EUS-TA) has emerged as an alternative method for sampling focal liver lesions. However, the utility of EUS-TA in assessing breast cancer biomarkers remains unclear.

Aim

To evaluate the diagnostic performance of EUS-TA, including its ability to assess biomarkers in liver metastases from breast cancer.

Methods

This single-center, retrospective observational study included patients who underwent EUS-TA for breast cancer liver metastases between 2016 and 2023. Clinical characteristics and specimen adequacy were analyzed. A pathologist classified the obtained tissue samples into four categories: (A) insufficient for diagnosis, (B) diagnosis possible only at the cytology level, (C) histological evaluation possible, but additional immunostaining for biomarkers not feasible, and (D) histological evaluation and additional immunostaining for biomarkers feasible.

Results

Fifteen cases were included, with a median patient age of 68 years (all female). The median liver lesion size was 20 mm (range: 8–50 mm). The lesions were located in the left lobe in 12 cases and the right lobe in 3 cases. A 22G needle was used in 14 cases, while a 25G needle was used in 1 case. Specimen adequacy was classified as follows: category A in 1 case (6.6%), B in 2 cases (13.3%), C in 0 cases (0%), and D in 12 cases (80%). Biomarker evaluation was feasible in the majority of cases. No procedure-related adverse events were observed.

Conclusion

EUS-TA is a valuable method for obtaining tissue samples from breast cancer liver metastases, enabling biomarker assessment in most cases.

背景：评估病理标本中的生物标志物，如雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体-2 (HER2)，对指导乳腺癌治疗至关重要。由于原发和转移性病变的生物标志物表达可能不同，因此建议在可行的情况下对转移部位进行活检。肝脏是乳腺癌常见的转移部位，经皮活检传统上是标准的方法。最近，内镜超声引导下的组织采集（EUS-TA）已成为肝脏局灶性病变采样的一种替代方法。然而，EUS-TA在评估乳腺癌生物标志物方面的应用仍不清楚。目的：评估EUS-TA的诊断性能，包括其评估乳腺癌肝转移生物标志物的能力。方法：这项单中心、回顾性观察性研究纳入了2016年至2023年间接受EUS-TA治疗的乳腺癌肝转移患者。分析临床特点及标本的充分性。病理学家将获得的组织样本分为四类：(A)不足以进行诊断，(B)只能在细胞学水平上进行诊断，(C)可以进行组织学评估，但不可进行额外的生物标志物免疫染色，(D)组织学评估和额外的生物标志物免疫染色可行。结果：纳入15例，患者中位年龄为68岁（均为女性）。肝病变中位大小为20mm（范围：8- 50mm）。病变位于左叶12例，右叶3例。22G针14例，25G针1例。标本充分性：A类1例（6.6%），B类2例（13.3%），C类0例（0%），D类12例（80%）。在大多数情况下，生物标志物评估是可行的。未观察到与手术相关的不良事件。结论：EUS-TA是一种有价值的获取乳腺癌肝转移组织样本的方法，在大多数情况下可以进行生物标志物评估。

{"title":"Endoscopic Ultrasound-Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment","authors":"Yuichi Takano, Naoki Tamai, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Fumitaka Niiya, Naotaka Maruoka, Tatsuya Yamagami, Masatsugu Nagahama","doi":"10.1002/cnr2.70414","DOIUrl":"10.1002/cnr2.70414","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. Since biomarker expression may differ between primary and metastatic lesions, biopsy of metastatic sites is recommended whenever feasible. The liver is a common metastatic site for breast cancer, and percutaneous biopsy has traditionally been the standard approach. Recently, endoscopic ultrasound-guided tissue acquisition (EUS-TA) has emerged as an alternative method for sampling focal liver lesions. However, the utility of EUS-TA in assessing breast cancer biomarkers remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate the diagnostic performance of EUS-TA, including its ability to assess biomarkers in liver metastases from breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center, retrospective observational study included patients who underwent EUS-TA for breast cancer liver metastases between 2016 and 2023. Clinical characteristics and specimen adequacy were analyzed. A pathologist classified the obtained tissue samples into four categories: (A) insufficient for diagnosis, (B) diagnosis possible only at the cytology level, (C) histological evaluation possible, but additional immunostaining for biomarkers not feasible, and (D) histological evaluation and additional immunostaining for biomarkers feasible.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifteen cases were included, with a median patient age of 68 years (all female). The median liver lesion size was 20 mm (range: 8–50 mm). The lesions were located in the left lobe in 12 cases and the right lobe in 3 cases. A 22G needle was used in 14 cases, while a 25G needle was used in 1 case. Specimen adequacy was classified as follows: category A in 1 case (6.6%), B in 2 cases (13.3%), C in 0 cases (0%), and D in 12 cases (80%). Biomarker evaluation was feasible in the majority of cases. No procedure-related adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>EUS-TA is a valuable method for obtaining tissue samples from breast cancer liver metastases, enabling biomarker assessment in most cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Rare Upper Thoracic and Cervical Esophageal GIST Resected Through Thoracoscopic Esophageal Mobilization and a Cervical Approach: A Case Report 经胸腔镜食管动员及颈椎入路切除罕见的上胸及颈段食管间质瘤1例。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-05 DOI: 10.1002/cnr2.70423

Kenjiro Ishii, Erica Nishimura, Yuki Tajima, Kumiko Hongo, Hiroto Fujisaki, Motohito Nakagawa, Kiminori Takano, Osahiko Hagiwara, Toshiyuki Enomoto, Takaharu Kiribayashi, Koji Asai, Takuya Nagata, Manabu Watanabe, Yoshihisa Saida

Background

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising from the digestive tract; however, esophageal GIST is a very rare entity and represents < 1% of all GIST cases. Furthermore, esophageal GIST is most commonly located in the lower esophagus, while esophageal GIST in the upper esophagus is rare among them. Therefore there are very few reports regarding their resection methods.

Case

This report describes a very rare resectable case of large upper esophageal GIST that extended to the cervical esophagus to be completely resected by performing thoracoscopic mobilization of the esophagus, followed by transection of the cervical esophagus via a cervical approach. The operative procedure was as follows: ensuring an adequate macroscopic margin for esophageal resection from within the thoracic cavity was judged to be difficult; therefore, only dissection of the thoracic and cervical esophagus was performed with thoracoscopic procedure, and the cervical esophagus was resected via a cervical approach. The abdominal procedure was carried out laparoscopically, and the specimen, including the tumor, was extracted from a small incision. Next, reconstruction using a gastric tube via a retrosternal approach was done. We also describe a literature review of upper esophageal GISTs.

Conclusion

The surgical approach of large tumors of the upper thoracic and cervical esophageal GIST, including esophageal resection and reconstruction methods, needs to be carefully considered in advance. A cervical approach for esophageal resection is considered useful when it is difficult to resect the tumor's proximal end within the thoracic cavity safely.

背景：胃肠道间质瘤（GIST）是消化道最常见的间质肿瘤；然而，食道间质瘤是一种非常罕见的实体，并具有代表性：本报告描述了一个非常罕见的可切除的病例，大的食道上段间质瘤延伸到颈段食道，通过胸腔镜下的食管活动，然后通过颈椎入路横切颈段食道。手术流程如下：判断在胸腔内食管切除术中保证足够的肉眼切缘是困难的；因此，我们在胸腔镜下仅对胸、颈段食道进行解剖，并经颈道入路切除颈段食道。腹部手术在腹腔镜下进行，包括肿瘤在内的标本从一个小切口中取出。接下来，通过胸骨后入路使用胃管进行重建。我们也对上食管gist进行了文献回顾。结论：胸上颈段食道间质瘤大肿瘤的手术入路，包括食道切除和重建方法，需要事先慎重考虑。当难以在胸腔内安全切除肿瘤近端时，经颈入路行食管切除术被认为是有用的。

{"title":"The Rare Upper Thoracic and Cervical Esophageal GIST Resected Through Thoracoscopic Esophageal Mobilization and a Cervical Approach: A Case Report","authors":"Kenjiro Ishii, Erica Nishimura, Yuki Tajima, Kumiko Hongo, Hiroto Fujisaki, Motohito Nakagawa, Kiminori Takano, Osahiko Hagiwara, Toshiyuki Enomoto, Takaharu Kiribayashi, Koji Asai, Takuya Nagata, Manabu Watanabe, Yoshihisa Saida","doi":"10.1002/cnr2.70423","DOIUrl":"10.1002/cnr2.70423","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising from the digestive tract; however, esophageal GIST is a very rare entity and represents < 1% of all GIST cases. Furthermore, esophageal GIST is most commonly located in the lower esophagus, while esophageal GIST in the upper esophagus is rare among them. Therefore there are very few reports regarding their resection methods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>This report describes a very rare resectable case of large upper esophageal GIST that extended to the cervical esophagus to be completely resected by performing thoracoscopic mobilization of the esophagus, followed by transection of the cervical esophagus via a cervical approach. The operative procedure was as follows: ensuring an adequate macroscopic margin for esophageal resection from within the thoracic cavity was judged to be difficult; therefore, only dissection of the thoracic and cervical esophagus was performed with thoracoscopic procedure, and the cervical esophagus was resected via a cervical approach. The abdominal procedure was carried out laparoscopically, and the specimen, including the tumor, was extracted from a small incision. Next, reconstruction using a gastric tube via a retrosternal approach was done. We also describe a literature review of upper esophageal GISTs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The surgical approach of large tumors of the upper thoracic and cervical esophageal GIST, including esophageal resection and reconstruction methods, needs to be carefully considered in advance. A cervical approach for esophageal resection is considered useful when it is difficult to resect the tumor's proximal end within the thoracic cavity safely.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70423","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HPV-Related Pelvic Squamous Cell Carcinoma of Unknown Primary: Two Case Studies 原发不明的hpv相关盆腔鳞状细胞癌：两例研究。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-03 DOI: 10.1002/cnr2.70402

Sepideh Soltani, Sahar Dashti, Maryam Garousi, Elahe Mirzaee, Majid Kaheh, Masoome Zolfaghari, Maryam Abolhasani, Alireza Nikoofar

Background

Cancer of unknown primary (CUP) presents diagnostic and management challenges, particularly when associated with rare subsets such as pelvic squamous cell carcinoma (SCC) of unknown primary origin. Human papillomavirus (HPV) is increasingly recognized as a prognostic and potentially predictive biomarker. HPV-associated SCCs often demonstrate better response to treatment and improved outcomes.

Cases

We present two cases of pelvic SCC with unknown primary origin, both positive for HPV genotype 16. Case 1 involved a 54-year-old woman with persistent abdominal pain who was diagnosed with an infiltrative 110 × 100 × 65 mm tumoral mass on the right side of the pelvic cavity, significantly involving the right iliac bone and right iliopsoas muscle; despite chemotherapy, the patient developed metastases. Case 2 featured a 46-year-old woman with progressive left lower limb pain, whose pelvic SCC was incidentally discovered on imaging with an 80 × 75 mm mass with an abnormal signal in the left iliac bone with extension to the left iliopsoas muscle involving the lower aspect of the iliopsoas muscle, and also involving the anterior aspect of the left sacral bone. She achieved a complete response to chemotherapy and chemoradiotherapy, with no evidence of recurrence during follow-up.

Conclusion

HPV-associated pelvic SCC of unknown primary presents both diagnostic complexity and therapeutic opportunity. The detection of HPV genotype 16 in both cases supports a growing body of case-based evidence suggesting a potential association with a favorable prognosis. However, further studies are needed to clarify its role in guiding management.

背景：原发不明的癌症（CUP）提出了诊断和治疗方面的挑战，特别是当与罕见亚群（如原发不明的盆腔鳞状细胞癌（SCC））相关时。人乳头瘤病毒（HPV）越来越被认为是一种预后和潜在预测的生物标志物。hpv相关的SCCs通常表现出更好的治疗反应和改善的结果。病例：我们提出两例骨盆鳞状细胞癌，原发来源不明，均为HPV基因型16阳性。病例1:54岁女性，持续性腹痛，诊断为盆腔右侧浸润性肿瘤团块（110 × 100 × 65 mm），明显累及右髂骨和右髂腰肌；尽管进行了化疗，病人还是出现了转移。病例2为46岁女性，进行性左下肢疼痛，影像学偶然发现盆腔鳞状细胞癌，肿块大小为80 × 75 mm，左侧髂骨有异常信号，延伸至左侧髂腰肌，累及髂腰肌下部，也累及左侧骶骨前部。她对化疗和放化疗完全有效，随访期间无复发迹象。结论：原发不明的hpv相关盆腔鳞状细胞癌具有诊断复杂性和治疗机会。在这两个病例中检测到HPV基因型16支持了越来越多的基于病例的证据，表明与良好预后的潜在关联。然而，需要进一步的研究来明确其在指导管理中的作用。

{"title":"HPV-Related Pelvic Squamous Cell Carcinoma of Unknown Primary: Two Case Studies","authors":"Sepideh Soltani, Sahar Dashti, Maryam Garousi, Elahe Mirzaee, Majid Kaheh, Masoome Zolfaghari, Maryam Abolhasani, Alireza Nikoofar","doi":"10.1002/cnr2.70402","DOIUrl":"10.1002/cnr2.70402","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer of unknown primary (CUP) presents diagnostic and management challenges, particularly when associated with rare subsets such as pelvic squamous cell carcinoma (SCC) of unknown primary origin. Human papillomavirus (HPV) is increasingly recognized as a prognostic and potentially predictive biomarker. HPV-associated SCCs often demonstrate better response to treatment and improved outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Cases</h3>\u0000 \u0000 <p>We present two cases of pelvic SCC with unknown primary origin, both positive for HPV genotype 16. Case 1 involved a 54-year-old woman with persistent abdominal pain who was diagnosed with an infiltrative 110 × 100 × 65 mm tumoral mass on the right side of the pelvic cavity, significantly involving the right iliac bone and right iliopsoas muscle; despite chemotherapy, the patient developed metastases. Case 2 featured a 46-year-old woman with progressive left lower limb pain, whose pelvic SCC was incidentally discovered on imaging with an 80 × 75 mm mass with an abnormal signal in the left iliac bone with extension to the left iliopsoas muscle involving the lower aspect of the iliopsoas muscle, and also involving the anterior aspect of the left sacral bone. She achieved a complete response to chemotherapy and chemoradiotherapy, with no evidence of recurrence during follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HPV-associated pelvic SCC of unknown primary presents both diagnostic complexity and therapeutic opportunity. The detection of HPV genotype 16 in both cases supports a growing body of case-based evidence suggesting a potential association with a favorable prognosis. However, further studies are needed to clarify its role in guiding management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis 阴茎鳞状细胞癌的人口统计学、临床特征和基于阶段的治疗和结果分析。

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-03 DOI: 10.1002/cnr2.70383

George M. Edwards, Lucas W. Ashley, Austin Holmes, Andrew W. Ju, Arjun Bhatt, Michael C. Larkins

Objectives

Penile squamous cell carcinoma (PSCC) is the most common penile cancer, accounting for ≥ 95% of cases, though it accounts for < 1% of all malignancies in men in the United States. We report an updated, stage-stratified analysis of the efficacy of surgery, radiation, and chemotherapy, including adjuvant and neoadjuvant chemoradiation, with further analysis of demographic and clinical factors.

Methods

Using the Surveillance, Epidemiology, and End Results (SEER) database, patients with PSCC diagnosed between 2000 and 2018 were identified. Five-year overall survival Cox regression analysis as well as univariate Kaplan–Meier analysis were performed, stratified by demographic and treatment variables.

Results

Two thousand seven hundred eight patients with PSCC were identified, with 57.8% being older than 65 years at diagnosis and 94.2% undergoing surgical intervention. With multivariate analysis, increasing disease stage (p < 0.001), age < 65 years (p < 0.001), lower disease grade (p < 0.001) were all associated with increased survival, while treatment with chemotherapy or radiotherapy was both associated with decreased survival (p = 0.002 and < 0.001, respectively). On univariate analysis, less invasive surgery was associated with increased survival among patients with low-grade, local (p < 0.001) or regional (p = 0.03) disease. Among those with high-grade disease, local excision was associated with increased survival (p = 0.008), though among those with regional disease no survival difference was seen (p = 0.86). Patients with regional disease saw increasing survival with four or more lymph nodes dissected (69% vs. 61%, respectively; p = 0.002).

Conclusions

Surgical management of penile SCC remains the mainstay treatment, and less invasive surgery is associated with noninferior or improved 5-year overall survival regardless of disease stage and grade. Patients with regional disease had increased survival when four or more lymph nodes were dissected. Future analysis of these trends stratified by disease subhistology and more granular analysis of the role of lymphadenectomy are warranted.

目的：阴茎鳞状细胞癌（PSCC）是最常见的阴茎癌，占病例的95%以上，方法：使用监测、流行病学和最终结果（SEER）数据库，确定2000年至2018年间诊断的PSCC患者。根据人口统计学和治疗变量进行分层，进行5年总生存率Cox回归分析和单因素Kaplan-Meier分析。结果：共发现2778例PSCC患者，其中57.8%的患者在确诊时年龄大于65岁，94.2%的患者接受了手术治疗。结论：阴茎鳞状细胞癌的手术治疗仍然是主要的治疗方法，微创手术与不降低或提高5年总生存率相关，无论疾病分期和分级如何。区域性疾病的患者，当四个或更多淋巴结被清扫时，生存率提高。未来的分析这些趋势分层的疾病亚组织学和更细粒度的分析，淋巴结切除术的作用是必要的。

{"title":"Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis","authors":"George M. Edwards, Lucas W. Ashley, Austin Holmes, Andrew W. Ju, Arjun Bhatt, Michael C. Larkins","doi":"10.1002/cnr2.70383","DOIUrl":"10.1002/cnr2.70383","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Penile squamous cell carcinoma (PSCC) is the most common penile cancer, accounting for ≥ 95% of cases, though it accounts for < 1% of all malignancies in men in the United States. We report an updated, stage-stratified analysis of the efficacy of surgery, radiation, and chemotherapy, including adjuvant and neoadjuvant chemoradiation, with further analysis of demographic and clinical factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the Surveillance, Epidemiology, and End Results (SEER) database, patients with PSCC diagnosed between 2000 and 2018 were identified. Five-year overall survival Cox regression analysis as well as univariate Kaplan–Meier analysis were performed, stratified by demographic and treatment variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Two thousand seven hundred eight patients with PSCC were identified, with 57.8% being older than 65 years at diagnosis and 94.2% undergoing surgical intervention. With multivariate analysis, increasing disease stage (<i>p</i> < 0.001), age < 65 years (<i>p</i> < 0.001), lower disease grade (<i>p</i> < 0.001) were all associated with increased survival, while treatment with chemotherapy or radiotherapy was both associated with decreased survival (<i>p</i> = 0.002 and < 0.001, respectively). On univariate analysis, less invasive surgery was associated with increased survival among patients with low-grade, local (<i>p</i> < 0.001) or regional (<i>p</i> = 0.03) disease. Among those with high-grade disease, local excision was associated with increased survival (<i>p</i> = 0.008), though among those with regional disease no survival difference was seen (<i>p</i> = 0.86). Patients with regional disease saw increasing survival with four or more lymph nodes dissected (69% vs. 61%, respectively; <i>p</i> = 0.002).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Surgical management of penile SCC remains the mainstay treatment, and less invasive surgery is associated with noninferior or improved 5-year overall survival regardless of disease stage and grade. Patients with regional disease had increased survival when four or more lymph nodes were dissected. Future analysis of these trends stratified by disease subhistology and more granular analysis of the role of lymphadenectomy are warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review 绝经前临床侵袭性转移性乳腺癌患者用一线含帕博西尼方案成功治疗：2例及文献综述

IF 1.9 Q4 ONCOLOGY

Cancer reports

Pub Date : 2025-12-03 DOI: 10.1002/cnr2.70417

Pei-An Fu, Ya-Chun Hsu, Hui-Ping Hsu, Tzu-Chien Lin, Wei-Pang Chung

Background

Palbociclib, which is an oral small-molecule cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, demonstrated its efficacy in hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer together with endocrine therapy. However, patients with visceral crises (symptomatic visceral dissemination) are recommended to consider chemotherapy rather than endocrine-based therapy. Currently, more reports and evidence support that patients with aggressive visceral metastasis can be effectively managed using both a CDK4/6 inhibitor and endocrine therapy.

Case

We report two premenopausal patients with HR+/HER2− metastatic breast cancer, whose diseases diffusely involved major organs and were successfully managed with palbociclib and endocrine therapies as the initial therapy.

Conclusion

In the two cases we reported, first-line palbociclib therapy shows adequate and timely responses for premenopausal HR+/HER2− metastatic breast cancer patients. Although not widely utilized, frontline therapy with palbociclib combined with endocrine treatments may be a choice for HR+/HER2− metastatic breast cancer patients experiencing severe visceral metastasis.

帕博西尼（Palbociclib）是一种口服小分子细胞周期蛋白依赖性激酶4和6 （CDK4/6）抑制剂，在激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）转移性乳腺癌中具有良好的疗效，并与内分泌治疗相结合。然而，内脏危象（症状性内脏播散）的患者建议考虑化疗而不是内分泌治疗。目前，越来越多的报道和证据支持CDK4/6抑制剂和内分泌治疗可以有效地控制侵袭性内脏转移患者。病例：我们报告了2例绝经前HR+/HER2-转移性乳腺癌患者，其疾病弥漫性累及主要器官，并成功地以帕博西尼和内分泌治疗作为初始治疗。结论：在我们报道的两例病例中，一线帕博西尼治疗对绝经前HR+/HER2-转移性乳腺癌患者有充分和及时的反应。帕博西尼联合内分泌治疗的一线治疗虽然没有被广泛应用，但可能是HR+/HER2-转移性乳腺癌患者发生严重内脏转移的一种选择。

{"title":"Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review","authors":"Pei-An Fu, Ya-Chun Hsu, Hui-Ping Hsu, Tzu-Chien Lin, Wei-Pang Chung","doi":"10.1002/cnr2.70417","DOIUrl":"10.1002/cnr2.70417","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Palbociclib, which is an oral small-molecule cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, demonstrated its efficacy in hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer together with endocrine therapy. However, patients with visceral crises (symptomatic visceral dissemination) are recommended to consider chemotherapy rather than endocrine-based therapy. Currently, more reports and evidence support that patients with aggressive visceral metastasis can be effectively managed using both a CDK4/6 inhibitor and endocrine therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>We report two premenopausal patients with HR+/HER2− metastatic breast cancer, whose diseases diffusely involved major organs and were successfully managed with palbociclib and endocrine therapies as the initial therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In the two cases we reported, first-line palbociclib therapy shows adequate and timely responses for premenopausal HR+/HER2− metastatic breast cancer patients. Although not widely utilized, frontline therapy with palbociclib combined with endocrine treatments may be a choice for HR+/HER2− metastatic breast cancer patients experiencing severe visceral metastasis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 12","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145666449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0